KüçükukurMBiniciR.FIB-4 Index – predictive noninvasive tool in patients with myocardial infarction with non-obstructive coronary arteries. Angiology. 2026. In press.
2.
ZhangWChenYZhuLPengSJinMYinJ.Prognostic value of the FIB-4 index in patients with myocardial infarction with non-obstructive coronary arteries. Int J Cardiol. 2026;445:134045.
3.
KouvariMChrysohoouCDamigouE, et al. Non-invasive tools for liver steatosis and steatohepatitis predict incidence of diabetes, cardiovascular disease and mortality 20 years later: the ATTICA cohort study (2002-2022). Clin Nutr. 2024;43(3):900-908.
4.
SeoYGPolyzosSAParkKHMantzorosCS.Fibrosis-4 index predicts long-term all-cause, cardiovascular and liver-related mortality in the adult Korean population. Clin Gastroenterol Hepatol. 2023;21:3322-3335.
5.
KokkorakisMMuzurovićEVolčanšekŠ, et al. Steatotic liver disease: pathophysiology and emerging pharmacotherapies. Pharmacol Rev. 2024;76:454-499.
6.
MuzurovićERizzoMMikhailidisDP.Obesity and nonalcoholic fatty liver disease in type 1 diabetes mellitus patients. J Diabetes Complications. 2022;36:108359.
7.
MuzurovićEKraljevićIVolčanšekŠ.Letter: metabolic dysfunction-associated steatotic liver disease: a silent whisper to the heart?Angiology. 2025;30:33197251407732.
8.
StefanakisKMingroneGGeorgeJMantzorosCS.Accurate non-invasive detection of MASH with fibrosis F2-F3 using a lightweight machine learning model with minimal clinical and metabolomic variables. Metabolism. 2025;163:156082.
9.
MuzurovićEKatsikiNVolčanšekŠPlesciaFRizzoMMantzorosCS.Emerging incretin- and multi-agonist-based treatments – the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond. Metabolism. 2026;177:156494.
10.
MuzurovićEHaluzikMHorváthLVlachoBMauricioD.Incretin-based agents and metabolic dysfunction-associated steatotic liver disease. Curr Pharm Des. Published online July 9, 2025. doi:10.2174/0113816128378484250619080753
11.
MuzurovićEMMikhailidisDP.Diabetes mellitus and noncardiac atherosclerotic vascular disease-pathogenesis and pharmacological treatment options. J Cardiovasc Pharmacol Ther. 2021;26:25-39.
12.
BorozanSVujosevicSMikhailidisDPMuzurovicE.Metabolic dysfunction-associated steatohepatitis and cardiovascular disease prevention – is resmetirom useful?Curr Vasc Pharmacol. 2025;23:4-7.
13.
European Association for the Study of the Liver. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. J Hepatol. 2021;75:659-689.
14.
VolčanšekŠJanežARizzoMMuzurovićE. Monitoring the liver as a part of the cardio-renal-metabolic continuum – what is cooking and burning with non-invasive tests and treatment options?J Diabetes Complications. 2024;38:108875.
15.
MuzurovićETopićGTodorovićNRizzoMZečevićK.The prevalence and correlates of advanced fibrosis in patients with and without diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: a cross-sectional study. J Diabetes Complications. 2025;39:109147.
16.
KokkorakisMFolkertsmaPForteJCWolffenbuttelBHRvan DamSMantzorosCS.GDF-15 improves the predictive capacity of steatotic liver disease non-invasive tests for incident morbidity and mortality risk for cardio-renal-metabolic diseases and malignancies. Metabolism. 2025;163:156047.
17.
KouvariMValenzuela-VallejoLGuatibonza-GarciaV, et al. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: results from a large multi-center study. Metabolism. 2023;147:155666.
